Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 38K | 59 | 643 |
| Gross Profit | -5K | -5K | 19K | 34 | 448 |
| Operating Income | -2M | -2M | -3M | -30M | -15M |
| EBITDA | -2M | -3M | -2M | -30M | -15M |
| Net Income | -2M | -3M | -2M | -31M | -16M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.06
+13.21% today
1Y Change
-52.27%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
United Health Products, Inc. (UEEC) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.06 and down 52.3% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -28.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -28.4%, free cash flow +0.7% with operating margin 0.0% and ROIC 123.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UEEC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UEEC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UEEC Max Drawdown
-60.36%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UEEC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$643.0
+989.8% YoY
FY Net Income
-$15.7M
+48.6% YoY
Free Cash Flow
-$1.4M
-72.4% YoY
Revenue Growth
+0.0%
EPS Growth
-28.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 38K | 59 | 643 |
| Gross Profit | -5K | -5K | 19K | 34 | 448 |
| Operating Income | -2M | -2M | -3M | -30M | -15M |
| EBITDA | -2M | -3M | -2M | -30M | -15M |
| Net Income | -2M | -3M | -2M | -31M | -16M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 169K | 95K | 13K | 22K | 46K |
| Total Assets | 270K | 285K | 351K | 27K | 217K |
| Total Liabilities | 3M | 2M | 2M | 1M | 1M |
| Shareholder Equity | -2M | -2M | -2M | -1M | -953K |
| Total Debt | 1M | 785K | 688K | 219K | 560K |
| Net Debt | 937K | 689K | 674K | 197K | 514K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-60.1% YoY
Capital Expenditures
101K
Free Cash Flow
1M
-72.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
80.6%
Debt / Equity
-0.53x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.